Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin
We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS. The quality-of-life indicators were measured at baseline and conclusion for five domains on the PCOS questionnaire, with equal improvement in scores in both placebo and metformin groups, suggesting that the addition of metformin does not add improvement to quality-of-life measures above those observed with lifestyle modification and OC treatment.
To access this article, please choose from the options below
M.H.-G. has nothing to disclose. K.D. has nothing to disclose. L.K. has nothing to disclose. D.G. has nothing to disclose. K.H. has nothing to disclose.
Supported by National Institutes of Health grant K23 HD043881-01A1 (K.M.H.) and grant UL1 RR 024160 from the National Center for Research Resources to the University of Rochester, Rochester, New York.
PII: S0015-0282(09)03458-X
doi:10.1016/j.fertnstert.2009.08.006
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

